Karyopharm Therapeutics Inc. Q3 2025 Earnings Recap

KPTI Q3 2025 November 5, 2025

Get alerts when KPTI reports next quarter

Karyopharm Therapeutics reported a strong Q3 2025, with total revenue rising 13% year-over-year to $44 million, driven by solid performance from its XPOVIO product line and significant advancements in clinical development.

Earnings Per Share Miss

$-3.82 vs $-3.47 est.

-10.1% surprise

Revenue Beat

44044000 vs 42062800 est.

+4.7% surprise

Market Reaction

1-Day -2.61%

5-Day +4.29%

30-Day +9.89%

See KPTI alongside your other holdings

Add to your portfolio — free

Key Takeaways

Completed enrollment in the pivotal Phase III SENTRY trial for frontline myelofibrosis, with top-line results expected in March and potential to redefine treatment standards.
Achieved U.S. net product revenue growth of 8.5%, totaling $32 million, reflecting ongoing strength in the multiple myeloma segment.
Secured approximately $100 million in financing, extending cash runway into Q2 2026 and supporting three core priorities: advancing clinical programs, growing the XPOVIO franchise, and maintaining financial discipline.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit KPTI on AllInvestView.

Previous Q2 2025